The role of screening and monitoring for bleomycin pulmonary toxicity

被引：21
|
作者：
Shippee, Brittney M. [1 ]
Bates, Jill S. [2 ]
Richards, Kristy L. [3 ,4 ]
机构：
[1] UAB Med, Dept Pharm, JT 1728-619 19th St South, Birmingham, AL 35249 USA
[2] Univ N Carolina, Med Ctr, Dept Pharm, Chapel Hill, NC USA
[3] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[4] Univ N Carolina, UNC Sch Med, Div Hematol Oncol, Chapel Hill, NC USA
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2016年 / 22卷 / 02期
关键词：
Bleomycin; pulmonary toxicity; monitoring; risk factors; CANCER; CHEMOTHERAPY;
D O I：
10.1177/1078155215574294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bleomycin-induced pulmonary toxicity can have a significant impact on patient outcomes. However, no guidelines for ideal screening and monitoring are available. This paper reviews the literature to identify the best way to monitor and reduce patient risk for bleomycin pulmonary toxicity. We have created evidence-based guidelines to help healthcare professionals identify patient risk factors and provide appropriate assessment and monitoring for patients receiving bleomycin therapy.
引用
收藏
页码：308 / 312
页数：5
相关论文
共 50 条
  • [31] COMPUTED-TOMOGRAPHY OF PULMONARY BLEOMYCIN TOXICITY
    MILLS, P
    HUSBAND, J
    SEMINARS IN ULTRASOUND CT AND MRI, 1990, 11 (05) : 417 - 422
  • [32] PULMONARY TOXICITY OF BLEOMYCIN - NEW PRACTICAL CONSIDERATIONS
    LACCOURREYE, H
    HAAS, C
    BASSET, JM
    HAQUET, JF
    ANNALES D OTO-LARYNGOLOGIE ET DE CHIRURGIE CERVICO-FACIALE, 1977, 94 (1-2): : 58 - 59
  • [33] PULMONARY TOXICITY STUDIES OF BLEOMYCIN AND TALLYSOMYCIN A IN MICE
    SCHLEIN, A
    SCHURIG, JE
    BACA, CD
    BRADNER, WT
    CROOKE, ST
    PHARMACOLOGIST, 1979, 21 (03): : 234 - 234
  • [34] DETECTING BLEOMYCIN PULMONARY TOXICITY - A CONTINUED CONUNDRUM
    COMIS, RL
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) : 765 - 767
  • [35] A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin
    Raphael, M. J.
    Lougheed, M. D.
    Wei, X.
    Karim, S.
    Robinson, A. G.
    Bedard, P. L.
    Booth, C. M.
    CURRENT ONCOLOGY, 2020, 27 (06) : 291 - 298
  • [36] LARGE-DOSE BLEOMYCIN THERAPY AND PULMONARY TOXICITY - POSSIBLE ROLE OF PRIOR RADIOTHERAPY
    SAMUELS, ML
    JOHNSON, DE
    HOLOYE, PY
    LANZOTTI, VJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 235 (11): : 1117 - 1120
  • [37] PEROXIDATION OF ARACHIDONIC-ACID BY BLEOMYCIN - A POSSIBLE MECHANISM OF BLEOMYCIN PULMONARY TOXICITY
    PASSERO, MA
    DISANTO, L
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 502 - 502
  • [38] A COMPARISON OF THE PULMONARY TOXICITY AND CHEMOTHERAPEUTIC ACTIVITY OF BLEOMYCIN-BAPP TO BLEOMYCIN AND PEPLEOMYCIN
    GINSBURG, E
    GRAM, TE
    TRUSH, MA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 12 (02) : 111 - 115
  • [39] ROLE OF PULMONARY-FUNCTION TESTS IN THE PREVENTION OF BLEOMYCIN PULMONARY TOXICITY DURING CHEMOTHERAPY FOR METASTATIC TESTICULAR TERATOMA
    LUCRAFT, HH
    WILKINSON, PM
    STRETTON, TB
    BRITISH JOURNAL OF CANCER, 1981, 44 (02) : 291 - 291
  • [40] ROLE OF PULMONARY-FUNCTION TESTS IN THE PREVENTION OF BLEOMYCIN PULMONARY TOXICITY DURING CHEMOTHERAPY FOR METASTATIC TESTICULAR TERATOMA
    LUCRAFT, HH
    WILKINSON, PM
    STRETTON, TB
    READ, G
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (02): : 133 - 139
12345